Articles les plus consultés

mardi 13 mars 2018

Oral glutamine under assessment by EMA for sickle cell disease | Hospital Healthcare Europe

Oral glutamine under assessment by EMA for sickle cell disease | Hospital Healthcare Europe: Emmaus has announced that the company’s Marketing Authorisation Application (MAA) for Xyndari has been fully validated and is now under assessment by the European Medicines Agency (EMA) for th

Aucun commentaire: